Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies

Gender Medicine
E A MacGregorXiaojun Hu


Triptans are a recommended first-line treatment for moderate to severe migraine. Using clinical trial data, we evaluated the safety and tolerability of frovatriptan as acute treatment (AT) and as short-term preventive (STP) therapy for menstrual migraine (MM). Data from 2 Phase III AT trials (AT1: randomized, placebo controlled, 1 attack; AT2: 12-months, noncomparative, open label) and 3 Phase IIIb STP trials in MM (MMP1 and MMP2: randomized, placebo controlled, double blind, 3 perimenstrual periods; MMP3: open label, noncomparative, 12 perimenstrual periods) were analyzed. In AT1, patients treated each attack with frovatriptan 2.5 mg, sumatriptan 100 mg, or placebo. In AT2, they used frovatriptan 2.5 mg. In MMP1 and MMP2, women administered frovatriptan 2.5 mg for 6 days during the perimenstrual period, taking a loading dose of 2 or 4 tablets on day 1, followed by once-daily or BID frovatriptan 2.5 mg, respectively; in MMP3, they used BID frovatriptan 2.5 mg. In AT1, which was previously published in part, group differences in adverse events (AEs) were analyzed using the Fisher exact test, and response rates were compared using logistic regression. Post hoc analyses of sustained pain-free status with no AEs (SNAE) and sustaine...Continue Reading


Jan 1, 1995·Intensive Care Medicine·J E Jayamaha, M K Street
Jun 1, 1995·Neurology·K M Kelly
Jul 17, 1998·Circulation·A MaassenVanDenBrinkP R Saxena
Dec 30, 1998·Journal of Cardiovascular Pharmacology·A A ParsonsG Feuerstein
May 25, 2002·Headache·P BuchanC Ward
May 25, 2002·Headache·Alan RapoportCharlotte Keywood
Mar 26, 2003·Neurology·N J GiffinA Macrae
Sep 27, 2003·Headache·R Michael Gallagher, Loretta Mueller
May 19, 2004·Headache·Arthur H ElkindCharlotte Keywood
May 19, 2004·Headache·David DodickUNKNOWN Triptan Cardiovascular Safety Expert Panel
May 20, 2004·Headache·Antoinette Maassen Van Den Brink, Pramod R Saxena
May 20, 2004·Headache·David W DodickStephen Silberstein
Jul 28, 2004·Neurology·Stephen D SilbersteinCharlotte Keywood
Jul 28, 2004·Neurology·E Anne MacGregor, Allan Hackshaw
Apr 29, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·L J StovnerJ Pascual
Jul 27, 2006·Headache·Jerome GoldsteinCarolyn R Sikes
Jan 31, 2007·Neurology·R B LiptonUNKNOWN AMPP Advisory Group
Jan 20, 2009·Recent Patents on CNS Drug Discovery·Robert BelvísJaime Kulisevsky
Aug 26, 2009·Neurology·Eve Klein, David Spencer

❮ Previous
Next ❯


May 6, 2011·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Gianni AllaisGennaro Bussone
Jun 1, 2012·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Gianni AllaisGennaro Bussone
May 25, 2013·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Gianni AllaisChiara Benedetto
May 31, 2012·Current Pain and Headache Reports·Barbara CasollaPaolo Martelletti
Mar 14, 2013·Therapeutic Advances in Neurological Disorders·Gianni Allais, Chiara Benedetto
Sep 15, 2010·Drugs·E Anne MacGregor
Jul 3, 2013·Dental Clinics of North America·Rafael Benoliel, Eli Eliav
Sep 30, 2010·The Journal of Headache and Pain·Anna FerrariEmilio Sternieri
Jan 10, 2012·Headache·Andrew HersheyScott Powers
Jan 29, 2017·Expert Opinion on Pharmacotherapy·Amanda E Macone, Michael D Perloff
Feb 15, 2017·The Australian and New Zealand Journal of Psychiatry·Alexandra P MetseJenny A Bowman
Feb 16, 2019·Clinical Trials : Journal of the Society for Clinical Trials·Thomas Permutt
Mar 6, 2019·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Stewart J Tepper
Mar 21, 2018·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Philip R Holland, Peter J Goadsby
Mar 13, 2012·Current Opinion in Supportive and Palliative Care·Gianluca Coppola, Jean Schoenen

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.